Recent Updates
Recently added Catalysts

APG-115

Phase 2

T-Prolymphocytic Leukemia | Small molecule | Oncology |Ascentage Pharma Group International - American Depository Shares|Last Updated: Nov 4, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment78
FDA Designations
No designations recorded
Clinical trial landscape

APG-115 · 5 trials · 9 indications

Phase 2 2Phase 1 3
NCT04496349A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLT-Prolymphocytic Leukemia
RECRUITING78 Analytics
NCT04785196APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid TumorsLiposarcoma
RECRUITING95 Analytics
PHASE2RECRUITING
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
T-Prolymphocytic Leukemia
NCT0449634978
Unlock trial analytics
PHASE2RECRUITING
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Liposarcoma
NCT0478519695
Unlock trial analytics
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
PurposeTREATMENT
Interventions
NameTypeDescription
APG-115DRUGQOD, 2 weeks on, 1 week off, in repeated 21-day cycles
APG-2575DRUGAPG-2575 given orally each day in cycle, in repeated 21-day cycles
ToripalimabDRUGToripalimab is administrated following CDE approved label dose, i.e.: 240 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
AzacitidineDRUG75 mg/m\^2 SC QD on Days 1- 7 (28-day cycle)
CytarabineDRUG1g/m\^2 IV QD on Days 3-7 (28-day cycle)
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT04275518studyFirstPostDate: changed
LOWMay 24, 2026NCT04785196studyFirstPostDate: changed
LOWMay 24, 2026NCT04496349studyFirstPostDate: changed
LOWMay 24, 2026NCT05701306studyFirstPostDate: changed